Clinical trial NCT06399432: Mediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms of Psoriasis in Patients Treated With Anti-IL-17 or Anti-IL-23 Inhibitors
Official title: Mediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms of Psoriasis in Patients Treated With Anti-IL-17 or Anti-IL-23 Inhibitors
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Psoriasis
Keywords: risankizumab
tildrakizumab
brodalumab
izekizumab
secukinumab
guselkumab
Lead sponsor: University Hospitals Cleveland Medical Center
Sponsor class: OTHER
First posted: 2024-05-03
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 94
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In this study, participants will have 3 or 4 total study visits over approximately 10 total weeks. There is a two week medication washout period in between the 1st and 2nd visits. This washout only applies if participants are using a prohibited psoriasis medication (such as topical steroids or oral psoriasis medications, like methotrexate). During the washout period, participants will have to stop the prohibited medication(s). If participants are not using any prohibited medications, then the 1st and 2nd visits can be combined and participants will only have 3 total in-person visits. Participants will be randomly assigned (by chance; like flipping a coin) to either the Mediterranean Diet or no dietary intervention. After 4 weeks on the diet, participants will start treatment with either Anti-IL-17 or Anti-IL-23 therapy. The biologic treatments will prescribed by the participants regular dermatologist and not as a part of the study.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of chronic plaque psoriasis for at least 12 months prior to Screening.
* Have moderate to severe plaque psoriasis at Baseline as defined by

  1. BSA ≥5% OR
  2. sPGA ≥3 (moderate to severe) OR
  3. PASI ≥5
* Must have been prescribed, per standard-of-care, an Anti-IL-17 or Anti-IL-23 therapy for psoriasis, which the patient has not yet started, but is willing to start during the study.

Eligible therapies are Secukinumab, Ixekizumab, Brodalumab, Guselkumab, Risankizumab, and Tildrakizumab.

* Must be in good health (except for psoriasis) as judged by the Investigator, based on medical history and physical examination.
* Must be eligible for a weight loss program, defined as being in good general health and having a BMI between 25 to 40.

Exclusion Criteria:

* Other than psoriasis, history of any clinically significant (as determined by the Investigator) cardiac (clinically advanced cardiovascular disease including stent, past history of MI, thrombotic event or arterial calcification), active or history of inflammatory bowel disease, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major uncontrolled disease.
* Any condition, including the presence of laboratory abnormalities, which would place the subject at unacceptable risk if he/she were to participate in the study.
* Any condition, including other inflammatory diseases or dermatologic conditions that confound the ability to interpret data from the study.
* Prior history of suicide attempt at any time in the subject's lifetime prior to screening or randomization, or major psychiatric illness requiring hospitalization within the last 3 years.
* Pregnant or breast-feeding.
* Have failed more than 3 systemic agents for treatment of psoriasis.
* History of allergy to any component of Anti-IL-17 or Anti-IL-23 therapies.
* Had a serious infection (including, but not limited to, hepatitis, pneumonia, sepsis, cellulitis, meningitis or pyelonephritis) or have been hospitalized for an infection. Subject must be cured of infection \> 4 weeks before Screening.
* Have a history of, or ongoing, chronic or recurrent infectious disease, including, but not limited to, chronic renal infection, chronic chest infection (e.g., bronchiectasis), sinusitis, recurrent urinary tract infection (e.g., recurrent pyelonephritis, chronic non-remitting cystitis), an open, draining, or infected skin wound or ulcer.
* Had a Bacillus Calmette-Guérin (BCG) vaccination within 1 year prior to screening.
* History of positive human immunodeficiency virus (HIV), or have congenital or acquired immunodeficiency (e.g., common variable immunodeficiency disease).
* Active substance abuse or a history of substance abuse within 6 months prior to Screening.
* Bacterial infections requiring treatment with oral or injectable antibiotics, or significant viral or fungal infections, within 4 weeks of Screening. Any treatment and cure for such infections must have been completed at least 4 weeks prior to Screening.
* Malignancy or history of malignancy, except for:

  1. treated \[i.e., cured\] basal cell or squamous cell in situ skin carcinomas;
  2. treated \[i.e., cured\] cervical intraepithelial neoplasia \[CIN\] or carcinoma in situ of the cervix with no evidence of recurrence within the previous 5 years.
* Have a known nut allergy.
* Currently participating in a supervised dietary program.
* Use of psoriasis therapy 2 weeks prior to Baseline (including, but not limited to, topical corticosteroids, retinoids or vitamin D analog preparations, tacrolimus, pimecrolimus, anthralin/dithranol, cyclosporine, corticosteroids, methotrexate, retinoids, mycophenolate, thioguanine, hydroxyurea, sirolimus, sulfasalazine, azathioprine, fumaric acid esters, TNF inhibitors IL-17 inhibitors, IL-12/23 inhibitors, or phototherapy).

Exceptions: Low-potency corticosteroids will be allowed as background therapy and restricted to treatment of the face, axillae, and groin in accordance with the manufacturers' suggested usage during the course of the study (this restricted usage should be documented). Subjects with scalp psoriasis will be permitted to use coal tar shampoo and/or salicylic acid scalp preparations on scalp lesions. An unmedicated skin moisturizer (e.g. Eucerin®) will be also permitted for body lesions only. Subjects should not use these topical treatments within 24 hours prior to the clinic visit.

* Use of any investigational drug within 2 weeks prior to Baseline.
* Prolonged sun exposure or use of tanning booths or other ultraviolet (UV) light sources.
* Currently flaring or unstable psoriasis.

Primary outcomes:
measure: Percentage of participants who had a change in blood monocytes profiles.
timeFrame: Baseline, 10 weeks
measure: Percentage of participants who had a change in T-cell profiles.
timeFrame: Baseline, 10 weeks
measure: Change in blood monocyte profile.
timeFrame: Baseline, 10 weeks
measure: Change in T-cell profiles.
timeFrame: Baseline, 10 weeks
Secondary outcomes:
measure: Change in serum biomarkers.
timeFrame: Baseline, 10 weeks
measure: Change in gut microbiome.
timeFrame: Baseline, 10 weeks
measure: Change in single cell gene expression.
timeFrame: Baseline, 10 weeks
measure: Change in metabolomics profile.
timeFrame: Baseline, 10 weeks
measure: Change in serum chemistries.
timeFrame: Baseline, 10 weeks
measure: Change in complete blood cell count.
timeFrame: Baseline, 10 weeks
Other outcomes:
Locations:
city: Cleveland
country: United States
facility: University Hospitals Cleveland Medical Center
state: Ohio
Study officials:
affiliation: University Hospitals Cleveland Medical Center
name: Neil Korman, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University Hospitals Cleveland Medical Center
name: Jordan K Kahle, MD
role: PRINCIPAL_INVESTIGATOR
References: